PE20010994A1 - Composiciones de liberacion dual de un inhibidor de la ciclooxigenasa-2 - Google Patents

Composiciones de liberacion dual de un inhibidor de la ciclooxigenasa-2

Info

Publication number
PE20010994A1
PE20010994A1 PE2000001395A PE0013952000A PE20010994A1 PE 20010994 A1 PE20010994 A1 PE 20010994A1 PE 2000001395 A PE2000001395 A PE 2000001395A PE 0013952000 A PE0013952000 A PE 0013952000A PE 20010994 A1 PE20010994 A1 PE 20010994A1
Authority
PE
Peru
Prior art keywords
inhibitor
fraction
cyclooxygenase
release compositions
solid particles
Prior art date
Application number
PE2000001395A
Other languages
English (en)
Inventor
Randy J Wald
Subhash Desai
Sreekant Nadkarni
Gary A Debrincat
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of PE20010994A1 publication Critical patent/PE20010994A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A UNA COMPOSICION ORAL QUE CONTIENE UNA FRACCION DE UN INHIBIDOR DE CICLOOXIGENASA 2 DE BAJA SOLUBILIDAD EN AGUA, UTILIZANDOSE DE 10mg A 400mg; SE ENCUENTRA EN SOLUCION EN UN SOLVENTE COMO POLIETILENGLICOL, Y/O EN FORMA DE PARTICULAS SOLIDAS DE LIBERACION INMEDIATA CON UN TAMANO D90 DE 1µm; EN FORMA DE GRANULOS O PERLAS; UNA SEGUNDA FRACCION DE DICHA DROGA DE UTILIZANDOSE DE 10mg A 400mg PRESENTE EN PARTICULAS SOLIDAS CON UN TAMANO DE PARTICULA MAYOR DE 25µm O PARTICULAS DE LIBERACION CONTROLADA, LENTA, PROGRAMADA, CALCULADA, POR PULSACIONES, SOSTENIDA, EXTENDIDA, SIENDO LA RAZON DE LAS FRACCIONES DE 10:1 A 1:10; SIENDO EL INHIBIDOR DE FORMULA I DONDE R3 ES METILO, AMINO; R4 ES H, ALQUILO C1-C4, ALCOXI; X ES N, CR5; R5 ES H, HALOGENO; Y E Z SON C, N QUE DEFINEN ATOMOS ADYACENTES DE UN ANILLO DE 5-6 MIEMBROS COMO CICLOPENTENONA, FURANONA, METILPIRAZOL, ISOXAZOL, DE PREFERENCIA CELECOXIB
PE2000001395A 1999-12-22 2000-12-22 Composiciones de liberacion dual de un inhibidor de la ciclooxigenasa-2 PE20010994A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17173899P 1999-12-22 1999-12-22
US18160400P 2000-02-10 2000-02-10
US20227000P 2000-05-05 2000-05-05

Publications (1)

Publication Number Publication Date
PE20010994A1 true PE20010994A1 (es) 2001-09-21

Family

ID=27390015

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001395A PE20010994A1 (es) 1999-12-22 2000-12-22 Composiciones de liberacion dual de un inhibidor de la ciclooxigenasa-2

Country Status (26)

Country Link
US (1) US7220434B2 (es)
EP (1) EP1239857B1 (es)
JP (1) JP2003518062A (es)
KR (1) KR100717549B1 (es)
CN (1) CN1230167C (es)
AT (1) ATE323485T1 (es)
AU (1) AU780774C (es)
BR (1) BR0016705A (es)
CA (1) CA2394232C (es)
CY (1) CY1105050T1 (es)
CZ (1) CZ300745B6 (es)
DE (1) DE60027464T2 (es)
DK (1) DK1239857T3 (es)
ES (1) ES2258988T3 (es)
HK (1) HK1055677A1 (es)
IL (2) IL150353A0 (es)
MX (1) MXPA02006151A (es)
MY (1) MY127898A (es)
NO (1) NO20022987L (es)
NZ (1) NZ519467A (es)
PE (1) PE20010994A1 (es)
PL (1) PL201409B1 (es)
PT (1) PT1239857E (es)
SK (1) SK9032002A3 (es)
TW (1) TWI286073B (es)
WO (1) WO2001045706A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
US6924303B2 (en) 2000-06-13 2005-08-02 Wyeth Analgesic and anti-inflammatory compositions containing COX-2 inhibitors
AU2001282886A1 (en) * 2000-07-13 2002-01-30 Pharmacia Corporation Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
EP1322158B1 (en) * 2000-10-02 2012-08-08 USV Ltd. Sustained release pharmaceutical compositions containing metformin and method of their production
DK1443912T3 (da) * 2001-10-12 2008-01-21 Elan Pharma Int Ltd Sammensætninger med en kombination af umiddelbare og kontrollerede frisætningsegenskaber
AR037356A1 (es) * 2001-11-13 2004-11-03 Pharmacia Corp Forma de dosificacion oral de una prodroga de sulfonamida
WO2003053420A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Multiple-pulse extended release formulations of clindamycin
EP1469846A2 (en) * 2002-01-07 2004-10-27 Pharmacia Corporation Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
JP4906233B2 (ja) 2002-03-01 2012-03-28 ユニバーシティー オブ サウス フロリダ 少なくとも１種の有効薬剤成分を含有する多構成要素固相
MXPA05000232A (es) 2002-06-21 2005-06-17 Transform Pharmaceuticals Inc Composiciones farmaceuticas con disolucion mejorada.
US20060052432A1 (en) * 2002-09-20 2006-03-09 Julius Remenar Pharmaceutical compositions with improved dissolution
AU2003295846A1 (en) * 2002-11-26 2004-06-18 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
EP2339328A3 (en) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US20040186180A1 (en) * 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
US20050095299A1 (en) * 2003-10-30 2005-05-05 Wynn David W. Controlled release analgesic suspensions
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
CA2589167A1 (en) * 2004-11-23 2006-06-01 Pliva Hrvatska D.O.O. Extended release pharmaceutical composition of celecoxib
FR2881049B1 (fr) * 2005-01-24 2008-12-26 Vetoquinol Sa Sa Medicament destine a etre administre par voie orale comprenant un inhibiteur de la cyclo-oxygenase-2, et son procede de preparation
GB0501809D0 (en) * 2005-01-28 2005-03-09 Pharmakodex Ltd Anti-migraine formulations
US20100034887A1 (en) * 2005-12-23 2010-02-11 Lek Pharmaceuticals D.D. Bursting Pellets
KR100762847B1 (ko) * 2006-01-27 2007-10-04 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
KR100753480B1 (ko) * 2006-01-27 2007-08-31 씨제이 주식회사 잘토프로펜 함유 서방성 정제 및 그 제조방법
WO2008103420A1 (en) 2007-02-21 2008-08-28 The Regents Of The University Of Michigan Compositions and methods for tranquilizing heart muscle
US20090004231A1 (en) * 2007-06-30 2009-01-01 Popp Shane M Pharmaceutical dosage forms fabricated with nanomaterials for quality monitoring
US20100233272A1 (en) * 2007-11-15 2010-09-16 Leah Elizabeth Appel Dosage forms comprising celecoxib providing both rapid and sustained pain relief
WO2010002712A2 (en) * 2008-06-30 2010-01-07 3M Innovative Properties Company Method of crystallization
US8343524B2 (en) 2008-07-31 2013-01-01 Clarke Mosquito Control Products, Inc. Extended release tablet and method for making and using same
PL387415A1 (pl) * 2009-03-06 2010-09-13 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Kompozycja farmaceutyczna zawierająca celekoksyb oraz sposób jej wytwarzania
BRPI1013901A2 (pt) * 2009-04-29 2019-09-24 Rexahn Pharmaceuticals Inc formulação de clavulanato para neuroproteção e tratamento de distúrbios neurodegenerativos
US8563035B2 (en) * 2010-05-05 2013-10-22 Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi Oral tablet compositions of dexlansoprazole
EP2384746A3 (en) * 2010-05-05 2012-03-07 Sanovel Ilac Sanayi ve Ticaret A.S. Dual release oral tablet compositions of dexlansoprazole
CA2804926C (en) * 2010-07-09 2019-01-08 James Trinca Green Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
CN103462920A (zh) * 2012-06-06 2013-12-25 南京亿华药业有限公司 一种口服环加氧酶-2抑制剂塞来昔布的组合物
US10413520B2 (en) 2014-01-29 2019-09-17 Crystalgenomics, Inc. Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stability
KR101446601B1 (ko) * 2014-01-29 2014-10-07 크리스탈지노믹스(주) 5-(4-(아미노설포닐)페닐)-2,2-디메틸-4-(3-플루오로페닐)-3(2h)-퓨라논을 포함하는 약학적 조성물 및 캡슐 제형
AU2017376257A1 (en) 2016-12-14 2019-06-13 Druggability Technologies Ip Holdco Limited Pharmaceutical composition containing celecoxib
SG11202008715WA (en) 2018-03-15 2020-10-29 R P Scherer Technologies Llc Enteric softgel capsules

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0236571B2 (ja) * 1986-04-11 1990-08-17 Otsuka Pharma Co Ltd Jizokuseiseizai
IT1215726B (it) * 1988-01-18 1990-02-22 Alfa Wassermann Spa Formulazioni galeniche a cessione programmata.
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
AU699593B2 (en) * 1995-02-13 1998-12-10 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
EP1288206B1 (en) * 1996-04-12 2008-09-17 G.D. Searle LLC Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
JPH1017497A (ja) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
CN1277550A (zh) * 1997-09-11 2000-12-20 尼科梅德丹麦有限公司 非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
ES2249253T3 (es) * 1999-03-10 2006-04-01 G.D. Searle Llc Metodo y composicion para administrar un inhibidor de la ciclooxigenasa-2.
EP1274425A1 (en) * 2000-04-18 2003-01-15 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2 inhibitor

Also Published As

Publication number Publication date
CA2394232A1 (en) 2001-06-28
HK1055677A1 (en) 2004-01-21
EP1239857B1 (en) 2006-04-19
CN1433309A (zh) 2003-07-30
AU780774C (en) 2006-09-21
DK1239857T3 (da) 2006-07-31
US20040242640A1 (en) 2004-12-02
CZ300745B6 (cs) 2009-07-29
DE60027464D1 (de) 2006-05-24
CY1105050T1 (el) 2010-03-03
WO2001045706A1 (en) 2001-06-28
PT1239857E (pt) 2006-07-31
MY127898A (en) 2006-12-29
AU780774B2 (en) 2005-04-14
TWI286073B (en) 2007-09-01
DE60027464T2 (de) 2006-08-31
MXPA02006151A (es) 2004-09-06
IL150353A (en) 2008-07-08
NZ519467A (en) 2004-02-27
EP1239857A1 (en) 2002-09-18
NO20022987D0 (no) 2002-06-20
ES2258988T3 (es) 2006-09-16
JP2003518062A (ja) 2003-06-03
KR20020072554A (ko) 2002-09-16
KR100717549B1 (ko) 2007-05-11
SK9032002A3 (en) 2003-03-04
CN1230167C (zh) 2005-12-07
ATE323485T1 (de) 2006-05-15
BR0016705A (pt) 2002-09-24
PL201409B1 (pl) 2009-04-30
PL355715A1 (en) 2004-05-17
US7220434B2 (en) 2007-05-22
NO20022987L (no) 2002-08-21
CA2394232C (en) 2009-06-09
AU2586801A (en) 2001-07-03
IL150353A0 (en) 2002-12-01

Similar Documents

Publication Publication Date Title
PE20010994A1 (es) Composiciones de liberacion dual de un inhibidor de la ciclooxigenasa-2
CR8086A (es) Compuestos de 1,2,4-oxadiazol acido benzoico y su uso para supresion de mutaciones sin sentido
UA74391C2 (uk) Арил- або гетероарилконденсовані імідазоли як антизапальні і анальгетичні агенти
BR0211910A (pt) Derivados de tiazolila 2,4,5-trissubstituìdos e a atividade antiinflamatória dos mesmos
RU2004109815A (ru) Пирролопиримидины в качестве средств ингибирования цистеинпротеаз
AR108265A1 (es) Derivados de feniltriazol sustituidos con amida y usos de estos
EA200600527A1 (ru) Активирующее ppar соединение и содержащая его фармацевтическая композиция
UY33500A (es) Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina
AR065499A1 (es) Inhibidores de serino proteasas.composiciones farmaceuticas
AR081834A1 (es) N-[(het)arilalquil)]pirazolocarboxamidas o tiocarboxamidas y analogos heterosustituidos, composiciones funguicidas que los contienen y metodos para el control de hongos fitopatogenos en cultivos usando dichos compuestos o sus composiciones
HUP9800294A2 (hu) N-{2-hidroxi-3-[(szulfonil-alkanoil)-amino]-propil}-szulfonamid-származékok és az ezeket tartalmazó gyógyszerkészímények
AR046046A1 (es) Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
EA200401613A1 (ru) Лекарственное средство для лечения рака
CA2295063A1 (en) Indole compounds as anti-inflammatory/analgesic agents
AR060545A1 (es) Compuestos de benzoaxol y benzotiazol 6-0- sustituidos y metodos de inhibicion de la senalizacion de csf-1r. composiciones farmaceuticas
AR057855A1 (es) Derivados de pirazina y composicion farmaceutica
RU2015125591A (ru) БЕНЗИЛСУЛЬФОНАМИДНЫЕ ПРОИЗВОДНЫЕ КАК МОДУЛЯТОРЫ RORc
PE20231652A1 (es) Nuevo inhibidor de la secrecion de acido y uso del mismo
AR074807A1 (es) Derivados de 1, 3, 4-oxadiazol, composiciones farmaceuticas que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de la dgat1.
ATE502930T1 (de) Antibakterielle mittel
RU2010110603A (ru) Высококонцентрированные препараты 1-метилгептилового эфира флуроксипира, стабильные при низких температурах
PE20210478A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
RU2010151142A (ru) Замещенные хиназолины
AR040533A1 (es) Mezclas de herbicidas que actuan sinergisticamente
MA30523B1 (fr) Compose tricylique et utilisation pharmaceutique de celui-ci

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed